Literature DB >> 19684254

Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice.

K S Murnane1, N Murai, L L Howell, W E Fantegrossi.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA) is a substituted phenethylamine more commonly known as the drug of abuse "ecstasy." The acute and persistent neurochemical effects of MDMA in the mice are distinct from those in other species. MDMA shares biological effects with both amphetamine-type stimulants and mescaline-type hallucinogens, which may be attributable to distinct effects of its two enantiomers, both of which are active in vivo. In this regard, among the substituted phenethylamines, R(-)-enantiomers tend to have hallucinogen-like effects, whereas S(+)-enantiomers tend to have stimulant-like effects. In the present study, mice were trained to discriminate S(+)- or R(-)-MDMA from vehicle. Drug substitution tests were then undertaken with the structurally similar phenethylamine dopamine/norepinephrine releaser S(+)-amphetamine, the structurally dissimilar tropane nonselective monoamine reuptake inhibitor cocaine, the structurally similar phenethylamine 5-hydroxytryptamine (5-HT)(2A) agonist 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), and the structurally dissimilar mixed action tryptamine 5-HT(2A) agonist/monoamine reuptake inhibitor N,N-dipropyltryptamine (DPT). S(+)-amphetamine fully substituted in the S(+)-MDMA-treated animals but did not substitute for the R(-)-MDMA cue. 2C-T-7 fully substituted in the R(-)-MDMA-trained animals but did not substitute for the S(+)-MDMA cue. Cocaine and DPT substituted for both training drugs, but whereas cocaine was more potent in S(+)-MDMA-trained mice, DPT was more potent in R(-)-MDMA-trained mice. These data suggest that qualitative differences in the discriminative stimulus effects of each stereoisomer of MDMA exist in mice and further our understanding of the complex nature of the interoceptive effects of MDMA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19684254      PMCID: PMC2775256          DOI: 10.1124/jpet.109.156174

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  29 in total

Review 1.  Serotonergic receptor subtypes and hallucinogen-induced stimulus control.

Authors:  J C Winter; D J Fiorella; D M Timineri; R A Filipink; S E Helsley; R A Rabin
Journal:  Pharmacol Biochem Behav       Date:  1999-10       Impact factor: 3.533

Review 2.  New insights into the mechanism of action of amphetamines.

Authors:  Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

3.  Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity.

Authors:  B J Logan; R Laverty; W D Sanderson; Y B Yee
Journal:  Eur J Pharmacol       Date:  1988-08-02       Impact factor: 4.432

Review 4.  Relationship between the discriminative stimulus properties and subjective effects of drugs.

Authors:  C R Schuster; C E Johanson
Journal:  Psychopharmacol Ser       Date:  1988

5.  Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.

Authors:  M E Liechti; M R Saur; A Gamma; D Hell; F X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2000-10       Impact factor: 7.853

6.  Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse.

Authors:  William E Fantegrossi; Christina L Kiessel; Richard De la Garza; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

Review 7.  The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Authors:  A Richard Green; Annis O Mechan; J Martin Elliott; Esther O'Shea; M Isabel Colado
Journal:  Pharmacol Rev       Date:  2003-07-17       Impact factor: 25.468

8.  3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.

Authors:  Vincent Setola; Sandra J Hufeisen; K Jane Grande-Allen; Ivan Vesely; Richard A Glennon; Bruce Blough; Richard B Rothman; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

9.  MDMA-like behavioral effects of N-substituted piperazines in the mouse.

Authors:  H L Yarosh; E B Katz; A Coop; W E Fantegrossi
Journal:  Pharmacol Biochem Behav       Date:  2007-07-06       Impact factor: 3.533

10.  Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors.

Authors:  J F Nash; B L Roth; J D Brodkin; D E Nichols; G A Gudelsky
Journal:  Neurosci Lett       Date:  1994-08-15       Impact factor: 3.046

View more
  14 in total

1.  The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ("ecstasy"): a concurrent microdialysis and plasma analysis study.

Authors:  K S Murnane; H L Kimmel; K C Rice; L L Howell
Journal:  Horm Behav       Date:  2011-12-14       Impact factor: 3.587

2.  Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys.

Authors:  Jessica McClung; William Fantegrossi; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2010-03-23       Impact factor: 4.530

3.  Nonhuman primate positron emission tomography neuroimaging in drug abuse research.

Authors:  Leonard Lee Howell; Kevin Sean Murnane
Journal:  J Pharmacol Exp Ther       Date:  2011-02-11       Impact factor: 4.030

Review 4.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

5.  In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection.

Authors:  R Marshell; T Kearney-Ramos; L K Brents; W S Hyatt; S Tai; P L Prather; W E Fantegrossi
Journal:  Pharmacol Biochem Behav       Date:  2014-05-21       Impact factor: 3.533

6.  Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents.

Authors:  Michael B Gatch; Sean B Dolan; Michael J Forster
Journal:  Behav Pharmacol       Date:  2017-08       Impact factor: 2.293

7.  Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats.

Authors:  Kurt J Varner; Kyle Daigle; Peter F Weed; Peter B Lewis; Sarah E Mahne; Ananthakrishnan Sankaranarayanan; Peter J Winsauer
Journal:  Psychopharmacology (Berl)       Date:  2012-09-13       Impact factor: 4.530

8.  Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys.

Authors:  K S Murnane; W E Fantegrossi; J R Godfrey; M L Banks; L L Howell
Journal:  J Pharmacol Exp Ther       Date:  2010-05-13       Impact factor: 4.030

9.  In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity.

Authors:  William E Fantegrossi; Brenda M Gannon; Sarah M Zimmerman; Kenner C Rice
Journal:  Neuropsychopharmacology       Date:  2012-11-08       Impact factor: 7.853

10.  Stereoselective Effects of Abused "Bath Salt" Constituent 3,4-Methylenedioxypyrovalerone in Mice: Drug Discrimination, Locomotor Activity, and Thermoregulation.

Authors:  Brenda M Gannon; Adrian Williamson; Masaki Suzuki; Kenner C Rice; William E Fantegrossi
Journal:  J Pharmacol Exp Ther       Date:  2016-01-14       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.